Human medicines European public assessment report (EPAR): Prialt, ziconotide, Date of authorisation: 21/02/2005, Revision: 33, Status: Authorised
EU Innovation Network (EU-IN)
Radiopharmaceuticals EU-IN Horizon Scanning Report
PSUSA/00000073/202507
Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 16, Status: Authorised
Human medicines European public assessment report (EPAR): Jorveza, budesonide, Date of authorisation: 08/01/2018, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Date of authorisation: 22/07/2016, Revision: 14, Status: Withdrawn
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 15 April 2026, 09:30 (CEST) to 15 April 2026, 13:00 (CEST)
Orphan designation: risvutatug rezetecan Treatment of pulmonary neuroendocrine carcinoma, 20/10/2025 Positive
Orphan designation: fenfluramine hydrochloride Treatment of Rett syndrome, 20/10/2025 Positive